Citation Impact
Citing Papers
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Trends in antibiotic use among outpatients in New Delhi, India
2011
Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection
2016
Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology
2013
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Systemic deletion of Atp7b modifies the hepatocytes’ response to copper overload in the mouse models of Wilson disease
2021
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Cancer Statistics, 2021
2021 Standout
Validation of TaqMan® SNP genotyping specificity for rs12979860 of IL-28B: Modeling primer specificity in vitro
2014
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
2018
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Regulation of microRNA function in animals
2018 Standout
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report
2009
Global epidemiology and genotype distribution of the hepatitis C virus infection
2014
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
2015
From non-A, non-B hepatitis to hepatitis C virus cure
2015
Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
2018 StandoutNobel
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study
2012
Nonselective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis
2014
Management and endoscopic techniques for digestive foreign body and food bolus impaction
2012
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection
2012
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
2011
Hepatitis C
2015
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
2010
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
2016
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Dynamic Coinfection with Multiple Viral Subtypes in Acute Hepatitis C
2010
Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009
2011
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
2015
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
2005
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
2014 Standout
Interferon-based therapy of hepatitis C
2007
Portal hypertensive bleeding in cirrhosis
2016 Standout
Essential oils from aromatic herbs as antimicrobial agents
2011 Standout
von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis
2014
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection
2010
Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
2015
Wilson's disease and other neurological copper disorders
2014
Treatment of hepatitis C in difficult-to-treat patients
2015
Systemic treatment of hepatocellular carcinoma: An EASL position paper
2021
IL28B single nucleotide polymorphisms in the treatment of hepatitis C
2011
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
2020
Antibiotic resistance in the environment
2021 Standout
Genetics of IL28B and HCV—response to infection and treatment
2012
Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
2011
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
2015
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
2013
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial
2017
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells
2020 StandoutNobel
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
2015
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
2010
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
2007
Novel therapies for hepatitis C — one pill fits all?
2013
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
2015
Optimal therapy in genotype 1 patients
2009
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
2010
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
2016
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection
2013
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
2016
Hepatocellular carcinoma
2022 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011
Resistance patterns of Escherichia coli isolated from sewage sludge in comparison with those isolated from human patients in 2000 and 2009
2012
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4
2015 StandoutNobel
Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus
2014 StandoutNobel
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections
2014 StandoutNobel
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
2021
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
2017
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
2015
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
2020
Fluorescent chemosensors: the past, present and future
2017 Standout
Renal replacement therapy in critically ill liver cirrhotic patients—outcome and clinical implications
2017
Advances in Treatment of Wilson Disease
2017
Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
2017
Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis
2014
IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis
2013
In vivo bioluminescence imaging reveals copper deficiency in a murine model of nonalcoholic fatty liver disease
2016
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Screening for Hepatitis C Virus Infection in Adolescents and Adults
2020
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Novel urchin-like Co9S8 nanomaterials with efficient intrinsic peroxidase-like activity for colorimetric sensing of copper (II) ion
2017
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Management of Ingested Foreign Bodies in Children
2015 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG
2016 StandoutNobel
Proteases and protease inhibitors in infectious diseases
2017
Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection
2016
Towards a small animal model for hepatitis C
2009 StandoutNobel
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
2012
Ultrasound Elastography: Review of Techniques and Clinical Applications
2017 Standout
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Guidelines for the management of hemophilia
2012 Standout
Emerging concepts in immunity to hepatitis C virus infection
2013
Intravenous Silibinin as ‘Rescue Treatment’ for On-Treatment Non-Responders to Pegylated Interferon/Ribavirin Combination Therapy
2011
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD
2021
Works of A Maieron being referenced
Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
2012
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
2008
Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease
2013
Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
2009
Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations
2015
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
2008
Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection
2011
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
2014
Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort
2013
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)
2013
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
2011
Capsule retention in a Zenker’s diverticulum
2011
Ten years of antibiotic consumption in ambulatory care: Trends in prescribing practice and antibiotic resistance in Austria
2009
Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C
2010
A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
2013
65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS
2013
Durability of SVR in chronic hepatitis C patients treated with peginterferon‐α2a/ribavirin in combination with a direct‐acting anti‐viral
2013
Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin
2015
Follow‐up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin‐free treatment
2017
8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’
2006
SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients: ACG International Award
2014
Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
2009
Chronic hepatitis C in Austria, 1992–2006: genotype distribution and demographic factors
2010
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting
2016
82 Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): Interim results of a randomised controlled trial
2006